PXMTF (PHAXIAM Therapeutics) Total Assets: $0.00 Mil (As of Sep. 2023)


PXMTF PHAXIAM Therapeutics SA PXMTF
38 GF Score
Price $0.00
View Full Analysis

What is PHAXIAM Therapeutics Total Assets?

PHAXIAM Therapeutics PXMTF 38 Total Assets is $0.00 Mil as of Sep. 2023. GuruFocus rates PXMTF with a GF Score™ of 38/100.

PHAXIAM Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $0.00 Mil.

Total Assets is connected with ROA %. PHAXIAM Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 was -34.22%. Total Assets is also linked to Revenue through Asset Turnover. PHAXIAM Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 was 0.00.

PHAXIAM Therapeutics  (OTCPK:PXMTF) Total Assets Explanation

Total Assets is connected with ROA %.

PHAXIAM Therapeutics's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %=Net Income (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=-24.292/( (70.998+0)/ 1 )
=-24.292/70.998
=-34.22 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PHAXIAM Therapeutics's Asset Turnover for the quarter that ended in Sep. 2023 is

Asset Turnover
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=0/( (70.998+0)/ 1 )
=0/70.998
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PHAXIAM Therapeutics Total Assets Related Terms

PHAXIAM Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for PHAXIAM Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PHAXIAM Therapeutics Total Assets Chart

PHAXIAM Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.95 131.72 97.81 75.44 48.53

PHAXIAM Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.75 0.00 48.53 71.00 0.00
PXMTF
38GF Score
PHAXIAM Therapeutics SA PXMTF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PHAXIAM Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PHAXIAM Therapeutics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets=Total Equity (A: Dec. 2022 )+Total Liabilities (A: Dec. 2022 )
=24.879+23.649
=48.53

PHAXIAM Therapeutics's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets=Total Equity (Q: Sep. 2023 )+Total Liabilities (Q: Sep. 2023 )
=N/A+N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $0.00 Mil mean?
PHAXIAM Therapeutics (PXMTF) has a Total Assets of $0.00 Mil as of Sep. 2023. The total amount of assets as recorded on a company's balance sheet. View historical data on PHAXIAM Therapeutics and its competitors.
Is PHAXIAM Therapeutics' Total Assets too high?
PHAXIAM Therapeutics' current Total Assets is $0.00 Mil. Overall, PHAXIAM Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does PHAXIAM Therapeutics' Total Assets compare to VRTX and REGN?
PHAXIAM Therapeutics' Total Assets of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PHAXIAM Therapeutics and its competitors. PHAXIAM Therapeutics's current Total Assets is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PHAXIAM Therapeutics stock overvalued right now?
PHAXIAM Therapeutics (PXMTF) has a current Total Assets of $0.00 Mil. The current Total Assets is $0.00 Mil. PHAXIAM Therapeutics' overall GF Score™ is 38/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PHAXIAM Therapeutics (PXMTF), the current Total Assets is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PHAXIAM Therapeutics Business Description

Address 60 Avenue Rockefeller, Lyon, FRA, 69008
PHAXIAM Therapeutics SA is a clinical-stage biopharmaceutical company developing therapies for severe forms of cancer and orphan diseases. Its platform uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its product candidate eryaspase, also referred to as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple-negative breast cancer, or TNBC.
38GF Score

Get the complete analysis for PXMTF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price